Abstract
Objective
To evaluate the efficacy and long-term benefits of tamsulosin in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Methods
A total of 100 men diagnosed with CP/CPPS were randomly allocated to receive either 0.2 mg of tamsulosin daily or placebo for 6 months. Patients were followed up at 3, 6, 12, 18 and 30 months after initiation of treatment. The primary outcome variable was the change from baseline in the total and domain scores of the NIH-CPSI. Secondary variables used to evaluate efficacy of treatment included the following: peak urinary flow rate, post-voiding residual (PVR) volume and the International Index of Erectile Function (IIEF).
Results
The tamsulosin patients had modest satisfactory improvements compared to the placebo group during treatment. Six months after initiation of treatment, the mean decrement of total NIH-CPSI score in tamsulosin and placebo group were 7.5 ± 1.9 and 4.0 ± 2.3, respectively, P < 0.01. After cessation of therapy, the significant difference waned gradually. Two years after cessation of therapy, the mean decrement of total NIH-CPSI score in two groups were 3.0 ± 1.3 and 1.9 ± 0.9, respectively, P > 0.05. No differences were observed for data of patients classified as class III A or III B and data of peak urinary flow rate, PVR and the IIEF during the study period.
Conclusion
Our study shows that a 6-month course of tamsulosin ameliorated symptoms of CP/CPPS during treatment. However, these effects decreased gradually 6 months after cessation of treatment. This suggests that long-term tamsulosin may be indicated, particularly in the responders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nickel JC, Downey J, Hunter D, Clark J (2001) Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 165:842–845
Cornel EB, van Haarst EP, Schaarsbergc RW, Geels J (2005) The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III. Eur Urol 47:607–611
Ishigooka M, Zermann DH, Doggweiler R, Schmidt RA (2000) Similarity of distributions of spinal c-Fos and plasma extravasation after acute chemical irritation of the bladder and the prostate. J Urol 164:1751–1756
Nickel JC (2006) Alpha-blockers for the treatment of prostatitis-like syndromes. Rev Urol 8(suppl 4):S26–S34
Tugcu V, Tasci AI, Fazlioglu A, Gurbuz G, Ozbek E, Sahin S, Kurtulus F, Cek M (2006) A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 51(4):1113–1118
Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M et al (2008) Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 359(25):2663–2673
Nickel JC, Narayan P, McKay J, Doyle C (2004) Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 171(4):1594–1597
Cheah PY, Liong ML, Yuen KH et al (2004) Initial, long term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 64:881–886
Litwin MS, McNaughton-Collins M, Fowler FJ Jr et al (1999) The National Institutes of health chronic prostatitis symptom index (NIH-CPSI): development and validation of a new outcomes measure. J Urol 162:369–375
Propert KJ, Litwin MS, Wang Y et al (2006) Responsiveness of the national institutes of health chronic prostatitis symptom index (NIH-CPSI). Qual Life Res 15:299–305
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830
Duclos AJ, Lee CT, Shoskes DA (2007) Current treatment options in the management of chronic prostatitis. Ther Clin Risk Manag 3:507–512
Liao LM, Shi BY, Liang CQ (1999) Ambulatory urodynamic monitoring of external urethral sphincter behavior in chronic prostatitis patients. Asian Journal of Andrology 1(4):215–217
Andersson KE, Gratzke C (2007) Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 4:368–378
Ishigooka M, Nakada T, Hashimoto T et al (2002) Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate. Urology 59(1):139–144
Geppetti P, Nassini R, Materazzi S, Benemei S (2008) The concept of neurogenic inflammation. BJU Int 101(Suppl):2–6
Nickel JC, Narayan P, McKay J, Doyle C (2004) Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 171:1594–1597
Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom PJ (2003) Alfuzosin treatment for chronicprostatitis/chronic pelvic pain syndrome:a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 62:425–429
Chen Y, Song B, Jin XY, Xiong EQ, Zhang JH (2005) Possible mechanism of referred pain in the perineum and pelvis associated with the prostate in rats. J Urol 174:2405–2408
Li NC, Chen S, Yang XH, Du LD, Yang JY, Na YQ (2003) Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Invest 23(12):781–787
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, Y., Wu, X., Liu, J. et al. Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol 29, 381–385 (2011). https://doi.org/10.1007/s00345-010-0537-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-010-0537-3